Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch

Tonix Pharmaceuticals beats expectations, and Tonmya prescriptions grow, with over 4,200 prescriptions since launch.
Stocktwits on MSN

TNXP stock rises premarket: Investors cheer early traction for fibromyalgia drug despite weak Q4 print

CEO Seth Lederman said early trends show favorable prescriber uptake and repeat utilization. ・Investors are also watching TNX ...

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through ...

Tonix Pharma Uplists to Nasdaq Global Select Market

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 ...
MarketWatch

Stock Market Today: Nasdaq sets record closing high while Dow falls for eighth straight day, for first time in history

The U.S. stocks ended mostly higher on Monday, with tech stocks leading the gains, as investors await the Federal Reserve's policy meeting that concludes on Wednesday. Wednesday marked the first time ...